Informationen:
Fehler:
ID
36593
Beschreibung
Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient; ODM derived from: https://clinicaltrials.gov/show/NCT02069418
Link
https://clinicaltrials.gov/show/NCT02069418
Stichworte
Versionen (1)
- 24.05.19 24.05.19 -
Rechteinhaber
See clinicaltrials.gov
Hochgeladen am
24. Mai 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent NCT02069418
Eligibility Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent NCT02069418
Ähnliche Modelle
Eligibility Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent NCT02069418
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Age
Item
age over superior to 18
boolean
C0001779 (UMLS CUI [1])
Non-Small Cell Lung Carcinoma
Item
nsclc proved by a histological biopsy
boolean
C0007131 (UMLS CUI [1])
EGFR gene mutation Status Known | EGFR Activating Mutation Absent
Item
egfr mutation status known with no activating egfr mutation
boolean
C3266992 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0205309 (UMLS CUI [1,3])
C2984891 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0449438 (UMLS CUI [1,2])
C0205309 (UMLS CUI [1,3])
C2984891 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Indication Erlotinib | Status post Prior Therapy Quantity
Item
indication of erlotinib therapy after at least one previous therapy
boolean
C3146298 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C1135135 (UMLS CUI [1,2])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
Informed Consent
Item
patients who have signed an informed consent to participate in this study
boolean
C0021430 (UMLS CUI [1])
Life Expectancy
Item
life expectancy exceeding 12 weeks
boolean
C0023671 (UMLS CUI [1])
WHO Physical activity score
Item
who activity score between 0 and 2.
boolean
C0043237 (UMLS CUI [1,1])
C4482422 (UMLS CUI [1,2])
C4482422 (UMLS CUI [1,2])
Medical contraindication Erlotinib
Item
contraindication for the initiation of erlotinib
boolean
C1301624 (UMLS CUI [1,1])
C1135135 (UMLS CUI [1,2])
C1135135 (UMLS CUI [1,2])
Informed Consent Refused
Item
refusal to sign the consent
boolean
C0021430 (UMLS CUI [1,1])
C1705116 (UMLS CUI [1,2])
C1705116 (UMLS CUI [1,2])
Inflammatory disorder Progressive
Item
progressive inflammatory disease
boolean
C1290884 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0205329 (UMLS CUI [1,2])
HIV Infection
Item
infection with the hiv virus
boolean
C0019693 (UMLS CUI [1])
Malignant disease Other
Item
other malignant disease
boolean
C0442867 (UMLS CUI [1,1])
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy less than 12 weeks
boolean
C0023671 (UMLS CUI [1])
Adult Protection Law France
Item
major adults protected by french law
boolean
C0001675 (UMLS CUI [1,1])
C0412786 (UMLS CUI [1,2])
C0220866 (UMLS CUI [1,3])
C0016674 (UMLS CUI [1,4])
C0412786 (UMLS CUI [1,2])
C0220866 (UMLS CUI [1,3])
C0016674 (UMLS CUI [1,4])